Trial Profile
Pharmacokinetic study of osimertinib in NSCLC patients with body fluid
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Sep 2017
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- 19 Sep 2017 New trial record